Navigation Links
Artificial pump effectively backs up failing hearts
Date:4/2/2009

Patients with severe heart failure can be bridged to eventual transplant by a new, smaller and lighter implantable heart pump, according to a just-completed study of the device. Results of this third-generation heart assist device were reported at the 58th annual meeting of the American College of Cardiology on March 30.

The device, called a left ventricular assist device (LVAD), is the latest generation of heart assist devices. The LVAD was tested at five main sites: Washington University School of Medicine in St. Louis, the University of Minnesota, Mt. Sinai School of Medicine, Inova Fairfax Hospital and the University of Pittsburgh.

"LVADs have allowed us to support patients until they can receive a heart transplant, so they are called a bridge to transplant," says Gregory Ewald, M.D., a Washington University cardiologist at Barnes-Jewish Hospital and medical director of the Heart Failure, Cardiac Transplantation and Total Artificial Heart Program. "For patients whose hearts are failing and are awaiting transplantation, these devices can be lifesavers. Washington University is the only medical center in the region where patients can receive these devices at this time."

In addition to Ewald, associate professor of medicine, lead investigators in the trial included Nader Moazami, M.D., associate professor of surgery and surgical director of the Cardiac Transplantation and Total Artificial Heart Program at Washington University, and Andrew Boyle, M.D., associate professor of medicine at the University of Minnesota and medical director of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support. Boyle presented the findings at the ACC meeting.

An LVAD is implanted inside the chest cavity near the heart and is connected to the heart's left ventricle (pumping chamber). It assists the patient's weakened or damaged ventricle in pumping blood through the body. By restoring a normal blood flow, the device improves patients' health. Because it is powered by portable battery packs, patients usually go home while they wait for a heart transplant.

The LVAD used in this study, the VentrAssist, is termed a third-generation heart assist device. Measuring 2.5-inches across and weighing 10 ounces, the pump is considered an improvement over earlier devices because its size and light weight make it suitable for small adults and children. In addition, its pumping mechanism has no contacting parts for improved durability.

Patients who received the LVAD in the study were approved and listed for cardiac transplantation. The study considered the device successful if a patient survived until heart transplantation or survived at least 180 days after the device was implanted and remained qualified for heart transplantation. Eighty-five percent of patients met this measure of success.

Out of 98 patients who received the device, 60 were transplanted, 19 continued to be supported with the device and 19 died. The median time on LVAD support was 131 days. Adverse events reported during the trial included stroke and bleeding, and the number and type of adverse events was similar to other LVADs but better than that of first-generation VAD devices.

Answering standardized questionnaires for patients with heart failure, they reported a significantly improved quality of life after receiving the device, indicating that their heart failure was less apt to interfere with everyday activities such as housework, hobbies or sleeping or to affect their mood, ability to concentrate or energy level.

"Before implantation of the device, 80 percent of these patients were rated class four on the New York Heart Association scale they were short of breath at rest," Ewald says. "But by six months, 84 percent were in class one or two, meaning their heart failure symptoms were minimal or mild. All of them were able to go home with the device, and that allowed them to rehabilitate themselves their nutrition improved and they were in better shape, making them better candidates for heart transplantation."

The VentrAssist device pumps blood in a continuous flow in contrast to earlier heart assist pumps that pumped blood in pulses. It contains a spinning rotor that is suspended by blood within the pump housing and magnetically rotated. Since the impeller blades don't touch any part of the pump, the chance of damage to blood cells is lessened. With only one moving part, the pump is resistant to wear.

The positive results from this clinical study mean the VentrAssist will be submitted to the U.S. Food and Drug Administration for approval for use as a bridge to heart transplant. In the interim, Washington University School of Medicine will continue to provide the device to patients as part of a clinical trial.


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas
2. Artificial disc replacement as good or better than spinal fusion surgery
3. New Technology May Boost Artificial Arms
4. Weizmann Institute scientists create working artificial nerve networks
5. Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination
6. Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
7. AMA Supports Ban of Artificial Trans Fats in Restaurants and Bakeries Nationwide
8. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
9. Breast Cancer Action Targets Yoplait in Think Before You Pink Campaign; Calls for Yogurt Without Artificial Hormones
10. Researchers design model for automated, wearable artificial kidney
11. Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is ... winter seasons. One major study analyzing heart attacks among 138,602 people recorded a ... a given year. We would all agree of course–no time of year is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... Caloifornia (PRWEB) , ... December 07, 2016 , ... ... present the fifth annual Business Architecture Innovation Summit in Reston, VA on March ... world who will share a range of experiences from a cross-section of industries ...
(Date:12/6/2016)... Korea (PRWEB) , ... December 06, 2016 , ... ... Inc. have agreed to collaborate in developing a vaccine against the Middle East ... a vaccine can be available in South Korea for emergency deployment in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... i2i Population Health, a ... a vice president of sales. , “Ajdin understands that building a successful sales ... understand what each client needs, and is persistent in building towards a solution ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... program in the use of cannabinoids for the ... June, 2015 InMed initiated its COPD program using ... and potential active compounds that can be useful ... vitro assays using human lung fibroblasts (HFL-1 cell ...
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is an ... is inserted into the femoral artery in the leg ... to treat constricted blood vessels. These products are generally ... atherosclerosis – deposition of lipid substances in the blood ... market is projected to expand at a CAGR of ...
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology: